|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Clevidipine#Use in Specific Populations]] |
| {{Clevidipine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Use in Specific Populations==
| |
| | |
| ===8.1 Pregnancy===
| |
| | |
| ===Pregnancy Category C ===
| |
| | |
| There are no adequate and well-controlled studies of Cleviprex use in pregnant women. In animal studies, clevidipine caused increases in maternal and fetal mortality and length of gestation. Cleviprex should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
| |
| There was decreased fetal survival when pregnant rats and rabbits were treated with clevidipine during organogenesis at doses 0.7 times (on a body surface area basis) the maximum recommended human dose (MRHD) in rats and 2 times the MRHD in rabbits.
| |
| | |
| In pregnant rats dosed with clevidipine during late gestation and lactation, there were dose-related increases in maternal mortality, length of gestation and prolonged parturition at doses greater than or equal to 1/6 of the MRHD based on body surface area. When offspring of these dams were mated, they had a conception rate lower than that of controls. Clevidipine has been shown to cross the placenta in rats [see Nonclinical Toxicology (13.3)].
| |
| | |
| ===8.2 Labor and Delivery===
| |
| | |
| Cleviprex in the labor and delivery setting has not been established as safe and effective. Other [[calcium channel blockers]] suppress uterine contractions in humans. Pregnant rats treated with clevidipine during late gestation had an increased rate of prolonged parturition.
| |
| | |
| ===8.3 Nursing Mothers===
| |
| | |
| It is not known whether clevidipine is excreted in human milk. Because many drugs are excreted in human milk, consider possible infant exposure when Cleviprex is administered to a nursing woman.
| |
| | |
| ===8.4 Pediatric Use===
| |
| | |
| The safety and effectiveness of Cleviprex in children under 18 years of age have not been established.
| |
| | |
| ===8.5 Geriatric Use===
| |
| | |
| Of the 1406 subjects (1307 with [[hypertension]]) treated with Cleviprex in clinical studies, 620 were ≥65 years of age and 232 were ≥75 years of age. No overall differences in safety or effectiveness were observed between these and younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, for an elderly patient doses should be titrated cautiously, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CLEVIPREX (CLEVIDIPINE) EMULSION [THE MEDICINES COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=095081a0-1398-11dc-82e1-0002a5d5c51b | publisher = | date = | accessdate = 27 February 2014 }}</ref>
| |
| | |
| ==References ==
| |
| {{Reflist|2}}
| |
| | |
| {{Calcium channel blockers}}
| |
| | |
| [[Category:Calcium channel blockers]]
| |
| [[Category:Dihydropyridines]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Carboxylate esters]]
| |
| [[Category:Butyrates]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |